Literature DB >> 2502388

Lack of effect of aspartame or of L-phenylalanine on photically induced myoclonus in the baboon, Papio papio.

B S Meldrum1, N Nanji, R G Cornell.   

Abstract

The effects of large doses of L-phenylalanine and of aspartame on seizure susceptibility and severity have been assessed in baboons Papio papio from Senegal which show photosensitive epileptic responses similar to primary generalised epilepsy in man. L-Phenylalanine, 50, 150 or 450 mg/kg, or aspartame, 300 or 1000 mg/kg, were administered orally. Peak plasma L-phenylalanine concentrations of approximately 2000 mumoles/l occurred 1-4 h after the highest dose of L-phenylalanine or aspartame. The plasma L-phenylalanine to large neutral amino acid ratio increased approximately 30-fold at this time. Compared with water administration there were no changes in epileptic responses 1-5 h after either treatment. In this primate model of epilepsy acute increases in plasma phenylalanine concentration are neither pro- nor anticonvulsant.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502388     DOI: 10.1016/0920-1211(89)90051-x

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  Oral aspartame and plasma phenylalanine: pharmacokinetic difference between rodents and man, and relevance to CNS effects of phenylalanine. Short note.

Authors:  J D Fernstrom
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

2.  Aspartame and seizures.

Authors:  P C Jobe; J W Dailey
Journal:  Amino Acids       Date:  1993-10       Impact factor: 3.520

3.  Absence of an effect of aspartame on seizures induced by electroshock in epileptic and non-epileptic rats.

Authors:  P C Jobe; S M Lasley; R L Burger; A F Bettendorf; P K Mishra; J W Dailey
Journal:  Amino Acids       Date:  1992-06       Impact factor: 3.520

Review 4.  Pharmacological effects of phenylalanine on seizure susceptibility: an overview.

Authors:  P Y Sze
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.